Clinical trials: Influenza B
Healthy
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children
The purpose of this study is to determine the efficacy of CAIV-T in a diverse Asian population aged from 6 months to less than 36 months, in tropical and temperate climates, against culture-confirmed influenza illness.
- Trial name
- NCT00192244
- Testing
- CAIV-T, Liquid
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Haemophilus Influenza Type b
Exploratory Clinical Study of MT-2301
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
- Trial name
- NCT02140047
- Testing
- Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV
- Where
- Japan
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A\&B Panel Self Test in the hands of patients/lay-users.
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT06124638
- Testing
- Panbio™ COVID-19/Flu A&B Panel
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- Abbott Rapid Dx
COVID-19, Influenza A
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \& FLU A/B Test, and LumiraDx SARS-CoV-2 \& RSV Test at Point of Care Testing Sites.
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Trial name
- INSPIRE-2 (NCT05268939)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Where
- 8 sites in United States
- Volunteers
- 589 people
- Sponsor
- LumiraDx UK Limited
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction.
The primary purpose of this study is to validate the sensitivity and specificity of the iTreat Flu A+B Test and the ellume.lab Flu A+B Test in detecting influenza A and influenza B as compared to viral culture.
- Trial name
- NCT03248960
- Testing
- iTreat Flu A+B Test, ellume.lab Flu A+B Test, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
- Where
- 8 sites in Australia
- Volunteers
- 381 people
- Sponsor
- Ellume Pty Ltd
Influenza
QuickVue Influenza A+B Clinical Field Trial
A comparative study of different swab types used for collection of specimens for rapid inluenza testing
- Trial name
- NCT00491283
- Testing
- Swab Specimen Collection (QuickVue)
- Where
- Australia
- Sponsor
- Quidel Corporation
Influenza
A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)
The purpose of this study is to determine whether GC3110A (a QIV) is effective compared to GC Flu Pre-filled Syringe Inj. (a marketed TIV) after single intramuscular administration in Korean healthy adults.
- Trial name
- NCT02121782
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza Type A, Influenza Type B
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients…
- Conditions
- Influenza Type A, Influenza Type B, COVID-19
- Trial name
- NCT06928129
- Testing
- BinaxNOW™ COVID-19/Flu A&B Combo Self-Test
- Volunteers
- 700 people
- Sponsor
- Abbott Rapid Dx
COVID-19, Influenza A
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06734741
- Testing
- COVID/Flu Detect™ Rapid Self-Test
- Where
- 10 sites in United States
- Volunteers
- 899 people
- Sponsor
- InBios International, Inc.
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
This is a multi-center, comparative, two-arm, parallel-group, single-blind, phase III study to assess immunogenicity and safety of 4th LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) vaccination compared…
- Trial name
- NCT01251133
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- LG Life Sciences
Influenza Type A, Influenza Type B
Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza
Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China.
- Trial name
- NCT06507813
- Testing
- ADC189 tablets, Baloxavir Marboxil tablets, ADC189 granules
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd
PNAG-expressing Pathogenic Microbes Vaccine
A Study of AV0328 Administered to Healthy Adult Volunteers
AV0328 is a novel vaccine candidate intended to raise antibodies to the glucosamine backbone of naturally occurring Poly N-acetyl glucosamine (PNAG), a capsular polysaccharide expressed on the surface of a wide array of microbes.
- Trial name
- NCT02853617
- Testing
- AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alopexx Vaccine, LLC
Healthy
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.
- Trial name
- NCT01250795
- Testing
- HAI-05 Influenza Vaccine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Influenza, Human
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an…
- Trial name
- NCT03314662
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
- Where
- 20 sites in United States
- Volunteers
- 1,778 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza A
Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI
The goal of this prospective, digital randomized controlled trial is to evaluate the effectiveness of a predictive ILI detection algorithm and associated alerts during influenza season for adults living in the contigent United…
- Conditions
- Influenza, Influenza A, Influenza B, COVID-19
- Trial name
- NCT06229444
- Testing
- ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content
- Where
- United States
- Volunteers
- 17,043 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza A, Influenza Type B
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV \& COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative…
- Conditions
- Influenza A, Influenza Type B, Coronavirus Disease 2019, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06392451
- Testing
- LIAISON NES FLU A/B, RSV, & COVID-19, LIAISON PLEX Respiratory Flex Assay
- Where
- 4 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- DiaSorin Molecular LLC
Influenza
Study of the Ability of a Flu Vaccine to Prevent Flu Infection
The purpose of this study is to evaluate how effective the vaccine is at preventing subjects developing flu symptoms after they are directly exposed to flu virus.
- Trial name
- NCT00349037
- Testing
- Trivalent DNA vaccine with and without pPJV2012 administered by PMED
- Where
- United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- PowderMed
Influenza
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
This is a open label, prospective, pair comparison, randomised, multi-centre trial. The primary aim of this study to is to clinically validate the sensitivity and specificity of the Respirio Flu Test (RFT) in detecting Influenza…
- Trial name
- NCT01431768
- Testing
- Respirio Flu Test
- Where
- 2 sites in Australia
- Volunteers
- 250 people
- Sponsor
- Respirio Pty Ltd